2018 SUO Annual Meeting
Phoenix, Arizona (UroToday.com) Increased understanding of the genomic landscape of advanced and metastatic prostate cancer has led to potentially actionable targets. Pritchard et al. demonstrated that 12% of men with advanced or mPCa has germline mutations in DNA repair genes. This was irrespective of family history and age of onset. BRCA2 was most common, but there were numerous that accounted for just 1-2% of that 12%.